Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

AIM: To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS: Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunod...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:World J Hepatol
Prif Awduron: Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Baishideng Publishing Group Inc 2017
Pynciau:
Observational Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395804/
https://ncbi.nlm.nih.gov/pubmed/28469811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v9.i11.551
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg